

**ondine**



**For Immediate Release**

## **Ondine to Present at Canaccord Adams' 28th Annual Global Growth Conference in Boston.**

**Vancouver, Canada – Aug 6, 2008** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that its Chief Technology Officer, Dr. Nicolas Loebel, is scheduled to present at the 28<sup>th</sup> Annual Canaccord Adams Global Growth Conference at the Intercontinental Hotel in Boston, on Tuesday August 12<sup>th</sup>, 2008 at 1:00 p.m. Eastern Time.

Interested parties may access the live webcast by visiting the Company's website at [www.ondinebiopharma.com](http://www.ondinebiopharma.com). Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software downloads that may be required to join the webcast. An audio archive of the presentation will be available for approximately 60 days.

### **About Ondine Biopharma Corporation**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development facility in Bothell, Washington, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com)

### **Forward-Looking Statements:**

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.*

### **FOR FURTHER INFORMATION please contact:**

Carolyn Cross

Adam Peeler

Canaccord Adams Ltd

President and

Investor Relations

Nominated Adviser &

Chief Executive Officer

Ondine Biopharma Corporation

(604) 669-0555

ccross@ondinebiopharma.com

The Equicom Group Inc.

(416) 815-0700 ext. 225

apeeler@equicomgroup.com

Broker

Neil Johnson /

Ryan Gaffney

+4420 7050 6500